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Abstract
Recent X-ray crystallographic analyses of the mitochondrial cytochrome bc1 complex show ubiquinone binding at the Qi site, but attempts
to show binding of ubiquinol or ubiquinone at the Qo site have been unsuccessful, even though the binding of noncompetitive Qo site
inhibitors near the putative ubiquinol binding pocket is well established. We speculate that ubiquinol binds transiently to the Qo site only
when both heme bL and the iron sulfur cluster are in the oxidized form, an experimental condition difficult to obtain since ubiquinol will be
oxidized once bound to the site. Stable binding at the Qo site might be achieved by a nonoxidizable ubiquinol-like compound. For this
purpose, the isomers 2,3,4-trimethoxy-5-decyl-6-methyl-phenol (TMDMP) and 2,3,4-trimethoxy-5-methyl-6-decyl-phenol (TMMDP) were
synthesized from 2,3-dimethoxy-5-methyl-6-decyl-1, 4-benzoquinol (Q0C10) by controlled methylation and separated by TLC and HPLC.
The structures of TMDMP and TMMDP were established by 1H-13C-two-dimensional NMR. Both are competitive inhibitors of the
cytochrome bc1 complex, with TMDMP being the stronger one. Preliminary results suggest that TMDMP binds tightly enough to make X-
ray crystallography of inhibitor–bc1 complex co-crystals feasible. The binding site of TMDMP does not overlap with the binding sites of
stigmatellin, MOA-stilbene (MOAS), undecylhydroxydioxobenzothiazole (UHDBT) and myxothaizol.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The mitochondrial respiratory chain, which provides
more than 90% of the energy needed for aerobic cells,
contains four electron transfer complexes and an ATP
synthase complex [1–3]. The cytochrome bc1 complex is
the central segment of the respiratory chain in mitochondria.
It oxidizes ubiquinol and reduces cytochrome c with con-
comitant generation of a proton gradient and membrane
potential for ATP synthesis by ATP synthase [4,5].
The first crystal structure of cytochrome bc1 complex
from bovine heart mitochondria was solved at 2.9-A˚ reso-
lution in 1997 [6]. One year later, more complete structures
from different crystalline forms were reported [7–10].
These X-ray crystallographic analyses revealed binding of
ubiquinone at the Qi site of the complex. Surprisingly, none
of the reported structures for cytochrome bc1 complex
shows ubiquinone or ubiquinol binding at the Qo site,
although they show binding for Qo site inhibitors [11].
Since most of the Qo site inhibitors are reported to be
noncompetitive [12,13] inhibitors or having too high bind-
ing affinity that they cannot be released by substrate or other
inhibitors, their binding sites cannot be assumed to be the
binding site for ubiquinol at the Qo site without severe
reservation. Establishing the nature of ubiquinol binding at
the Qo site is very important in the mechanistic study of this
complex. The key feature of the Q-cycle mechanism [14–
16] is the bifurcation of ubiquinol oxidation at the Qo site.
This step cannot be established without detailed information
of ubiquinol binding at Qo site.
A possible explanation for the failure to detect ubiquinol
or ubiquinone binding at the Qo site is that ubiquinol
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binding at the Qo site is transient, occurring only when the
iron–sulfur cluster (2Fe2S) of the Reiske iron–sulfur pro-
tein (ISP) and heme bL are both in the oxidized state. This
experimental condition is difficult to obtain because once
ubiquinol binds at the Qo site, it immediately gives electrons
to 2Fe2S and to heme bL to become ubiquinone, which may
be only loosely bound to the Qo site and thus is not
detectable in the crystal structure. If this speculation is
correct, one would expect to see Q-binding at the Qo pocket
in cytochrome bc1 complex crystals loaded with a non-
oxidizable reduced Q derivatives, since the conditions for
ubiquinol binding, 2Fe2S and heme bL in oxidized state and
Q derivative in reduced state, are preserved.
Recently we synthesized two isomers of a reduced Q-like
compound, 2,3,4-trimethoxy-5-decyl-6-methyl-phenol
(TMDMP) and 2,3,4-trimethoxy-5-methyl-6-decyl-phenol
(TMMDP), to test this possibility. Unlike other Qo site
inhibitors of the cytochrome bc1 complex, both of these Q
derivatives inhibit the cytochrome bc1 complex competi-
tively, suggesting that they bind to the substrate-binding
site. Herein we report the synthetic procedure for and
structural identification of these two reduced Q-like com-
pounds. The inhibitor potency and the mode of inhibition of
the cytochrome bc1 complex by TMDMP and TMMDP are
analyzed with Lineweaver–Burk plots. That TMDMP or
TMMDP competes with substrate quinol for binding at the
ubiquinol oxidation site of the cytochrome bc1 complex is
further established by measuring the inhibitor potency of
TMDMP under various assay conditions. The effect of other
Qo site inhibitors on the TMDMP inhibition of cytochrome
bc1 complex is also examined. The binding site of TMDMP
in the cytochrome bc1 complex is briefly described.
2. Experimental procedure
2.1. Materials
Cytochrome c, Type III, sodium cholate and deoxycholic
acid were from Sigma. Dodecyl-h-D-maltoside (DM) was
purchased from Anatrace. 2,3-Dimethoxy-5-methyl-6-ger-
anyl-1, 4-benzoquinone (Q2), 2,3-dimethoxy-5-methyl-6-
decyl-1, 4-benzoquinone (Q0C10), and 2,3-dimethoxy-5-
methyl-6-pentyl-1, 4-benzoquinone (Q0C5) were synthesized
in our laboratory [17]. Other chemicals were of the highest
purity commercially available.
2.2. Synthesis of TMDMP and TMMDP
Two isomers, TMDMP and TMMDP, were synthesized
from 2,3-dimethoxy-5-methyl-6-decyl-1, 4-benzoquinol
(Q0C10H2) by controlled methylation [18]. Q0C10, 77 mg
(0.24 mmol), was dissolved in 0.35 ml of methanol and
shaken with 45-mg sodium borohydride (1.2 mmol) until
the solution became colorless. The mixture was treated with
1.4 ml of water and extracted with diethyl ether. The ether
extract was dried over MgSO4, filtered and evaporated to
obtain the reduced product, Q0C10H2, as colorless oil.
Q0C10H2 was dissolved in 0.5 ml of dry acetone, mixed
with 50 Al of methyl iodide and 33 mg of K2CO3. This
mixture was refluxed for 6–8 h with stirring. All described
steps were carried out under argon. The solution was filtered
and the filtrate was purified with Silica Gel G plates. The
thin layer plate was developed with a hexane/ethyl acetate
(9:1 v/v) mixture. TMDMP has a slightly lower mobility
(Rf = 0.53) than TMMDP does (Rf = 0.55) in this system.
Both compounds were eluted with ether; yields were 8.2%
and 20.6%, respectively. Since only small amounts of these
compounds were needed, no special effort was made to
improve the yields. Both TMDMP and TMMDP were
further purified by HPLC, using a C-18 column (3.9
150 mm) with 75% acetonitrile as the mobile phase. The
retention times were 16.5 and 14.8 min for TMDMP and
TMMDP, respectively, at a flow rate of 1.0 ml/min. The
structure of TMDMP and TMMDP was determined by
1H-13C-HMBC (heteronuclear multiple band correlation)
NMR using a 600-MHz NMR spectrometer.
2.3. Enzyme preparations and assays
Bovine heart mitochondrial cytochrome bc1 complex
was prepared as previously reported [19]. The purified
complex was dissolved in 50 mM Tris–Cl buffer, pH 7.8,
containing 0.66 M sucrose to a protein concentration of 20
mg/ml and frozen at  80 jC until use. Normally the
purified bc1 complex contains 10 nmol of cytochrome b
and 5.7 nmol of cytochrome c1 per milligram of protein. It
was reported that crystalline cytochrome bc1 complex has a
ratio of cytochrome b to cytochrome c1 of 2 and the excess
cytochrome c1 subfraction that appeared in the purified
sample was recovered in the mother liquid of crystallization
[20]. The concentrations of cytochromes b and c1 were
determined spectrophotometrically using millimolar extinc-
tion coefficients of DE562–575 nm = 28.5 cm
 1 mM 1 and
DE552–540 nm = 17.5 cm
 1 mM 1 for cytochromes b and c1,
respectively.
For activity assay, the cytochrome bc1 complex was
diluted with 50 mM phosphate buffer, pH 7.4, containing
1 mM EDTA and 0.01% dodecylmaltoside to a protein
concentration of 0.05 mg/ml. Diluted enzyme solution (10
Al) was added to 980 Al of an assay mixture containing 50
mM phosphate buffer, pH 7.4, containing 1 mM EDTA and
100 mM cytochrome c in the presence or absence of
inhibitor. The mixture was incubated for 1 min at 25 jC.
Activity was determined by measuring the reduction of
cytochrome c after addition of 5 Al of Q0C10H2 or other
reduced ubiquinol derivatives. A millimolar extinction
coefficient of 18.5 cm 1 mM 1 was used to calculate
the activity. Nonenzymatic reduction of cytochrome c,
determined under the same conditions in the absence of
the cytochrome bc1 complex, was subtracted from the
assay.
L. Zhang et al. / Biochimica et Biophysica Acta 1556 (2002) 226–232 227
2.4. Cytochrome bc1 complex–inhibitor co-crystallization
and X-ray diffraction data analysis
For co-crystallization of the cytochrome bc1 complex
with TMDMP, a fourfold molar excess of inhibitor was
added to the protein solution. This solution was set up for
crystallization as described [6,9]. Crystals grew in 2–4
weeks; they had a rectangular shape and ranged from 0.2
to 0.6 mm. They could be frozen at high glycerol concen-
tration, and they had the same symmetry and similar unit
cell dimensions as the native crystals [6,9]. X-ray diffraction
data were collected at the beamline 17-ID in the facilities of
the IMCA-CAT at the Advanced Photon Source (APS),
Argonne National Laboratory. The data were analyzed by
HKL2000, CNS and Xtal View [21–23].
3. Results and discussion
3.1. Synthesis, chemical structures and absorption proper-
ties of TMDMP and TMMDP
The structures of these two isomers are confirmed by 1H-
NMR, and 2-D NMR 1H-13C-HMBC. 1H NMR for
TMDMP (CDCl3) shows: d 5.52 (s, 1, OH), 3.86 (s, 3H,
OMe), 3.84 (s, 3H, OMe), 3.72 (s, 3H, OMe), 2.50 (t, 2H,
-CH2-decyl), 1.38–1.21 (m, 16H, (CH2)8 of decyl), 0.81 (t,
3H, Me of decyl) and 2.09 (s, 3H, Me); whereas 1H-NMR
for TMMDP (CDCl3) shows: d 5.47 (s, 1, OH), 3.86 (s,
3H, OMe), 3.84 (s, 3H, OMe), 3.69 (s, 3H, OMe), 2.52(t,
2H, -CH2- of decyl), 1.38–1.21(m, 16H, (CH2)8 of decyl),
0.81(t, 3H, Me of decyl) and 2.10 (s, 3H, Me). As
expected when D2O was added to the system, the peaks
of d 5.52 and 5.47 disappeared. Because TMDMP and
TMMDP are isomers, 1-D 1H-NMR spectrum is not
adequate for complete structure elucidation. Hence, 2-D
1H-13C HMBC NMR spectra were used to identify the
structure of and confirm the position of the substituents in
these two isomers. Table 1 shows NMR data in low field
(aromatic ring region) of TMDMP and TMMDP. Fig. 1A
and B shows 2-D NMR 1H-13C-HMBC spectrograms of
TMDMP and TMMDP, respectively.
In TMDMP (Fig. 1A), the hydroxyl H (d 5.52) shows
heteronuclear multiple bond couplings with C-1, C-2 and
C-6, indicating direct bonding to C-1, which bonds to both
C-2 and C-6. Furthermore, the methylene H (d 2.50) in the
decyl group shows correlation with C-5, C-4 and C-6,
showing bonding to C-5, which bonds to both C-2 and C-
6. The remaining three 3H singlets at d 3.86, 3.84 and 3.72
are assigned to the hydrogens of methoxy groups at C-2,
C-3 and C-4 based on 1H-13C HMBC correlations. In
TMMDP (Fig. 1B), the phenol ring is confirmed by the
presence of hydroxyl resonance at d 5.47, correlations with
ring carbons C-1, C-2 and C-6. Moreover, the 3H of the
methyl group interact with aromatic carbons C-4, C-5 and
C-6, while –CH2 (d 2.52) of the decyl group in TMMDP
interacts with aromatic carbons C-6, C-1 and C-5. These
NMR data confirm the chemical formula of TMDMP and
TMMDP given in Fig. 1.
Fig. 2 shows the absorption spectra of TMDMP in
neutral and alkaline aqueous solution. As expected the
absorption spectra of TMMDP are very similar (data not
shown). Both compounds have an absorption peak at 283
nm. The millimolar extinction coefficient for TMDMP and
TMMDP was determined to be 2 cm 1 mM 1 at 283 nm
in ethanol. Upon alkalization with sodium hydroxide, this
283-nm peak shifts to a high wavelength with a significant
increase in absorption intensity, indicating the dissociation
of a proton from the hydroxyl group. This result confirms
that these two isomers are indeed phenolic compounds.
The pKa of both compounds is estimated to be around
12.5.
3.2. Mode of inhibitions of cytochrome bc1 complex by
TMDMP and TMMDP
Fig. 3 shows the concentration-dependent inhibition of
the cytochrome bc1 complex by TMDMP and TMMDP.
When a given amount of complex was added to an assay
mixture containing 50 mM Na/K phosphate buffer, pH 7.0,
100 AM cytochrome c and varying amounts of TMDMP or
TMMDP, the rate of cytochrome c reduction, upon addition
of 50 AM of substrate ubiquinol-2, decreased as the con-
centration of TMDMP or TMMDP in the assay mixture
increased. These compounds are not very strong inhibitors.
Inhibitions of 60% and 40% were observed when 60 AM
TMDMP or TMMDP was present in the assay mixture (see
Fig. 3). The need for a high concentration of TMDMP or
Table 1




1H-13CHMBC Groups 1H yH
13C yC
1H-13CHMBC
C-1(-OH) 5.52 143.2 C-1,C-2,C-6 C-1(-OH) 5.47 143.1 C-1,C-2,C-6
C-2(-OCH3) 3.86 137.5 C-2,C-3,C-1 C-2(-OCH3) 3.86 137.5 C-2,C-1,C-3
C-3(-OCH3) 3.84 143.4 C-3,C-2,C-4 C-3(-OCH3) 3.84 143.5 C-3,C-2
C-4(-OCH3) 3.72 144.4 C-4 C-4(-OCH3) 3.69 144.6 C-4
C-5(-CH2-) 2.50 130.7 C-4,C-5,C-6 C-5(-CH3) 2.10 125.3 C-5,C-4,C-6
C-6(-CH3) 2.09 117.1 C-1,C-5,C-6 C-6(-CH2-) 2.52 122.7 C-1,C-5,C-6
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TMMDP to show partial inhibition is expected since these
two compounds are competitive inhibitors and they must
compete with the excess substrate ubiquinol-2 present in the
assay mixture.
Lineweaver–Burk analyses show that both TMDMP and
TMMDP are competitive inhibitors (Fig. 4) with a calcu-
lated Ki of 6.8 AM for TMDMP and 71.6 AM for TMMDP,
indicating that TMDMP is the stronger inhibitor than
TMMDP. The Km for Q0C10H2 is increased from 20 to
51.3 AM upon treatment with TMDMP. A slightly larger
increase in Km for Q0C10H2 (to 66.7 AM) was observed with
the TMMDP-treated enzyme.
The difference in the inhibitory potency of TMDMP and
TMMDP suggests that the two hydroxyl groups of ubiq-
uinol do not play an equal role in substrate binding. The
hydroxyl in the position meta to the long alkyl side chain is
apparently more important for binding than is hydroxyl
group in the position ortho to the side chain.
Although TMDMP and TMMDP are rather weak com-
petitive inhibitors, the structural similarity between them
and the substrate ubiquinol make them valuable for studying
Fig. 1. 1H-13C HMBC spectrum of the aromatic ring region of TMDMP (A) and TMMDP (B).
Fig. 2. Absorption spectra of TMDMP. The solid line shows the spectrum
measured in 20 mM phosphate buffer, pH 7.0, containing 0.05% DM. The
dashed line shows the spectrum in 0.1 N NaOH.
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the ubiquinol oxidation site in the cytochrome bc1 complex.
Preliminary results indicate that TMDMP binds tightly
enough to make feasible X-ray crystallography on inhib-
itor–protein complex co-crystals.
3.3. The effect of the alkyl side-chain of ubiquinol on the
inhibition of the cytochrome bc1 complex by TMDMP
It has been reported [24] that the cytochrome bc1 com-
plex catalyzes the oxidation of quinol derivatives with an
efficiency directly proportional to the number of carbons in
the quinol side chain, up to 10 carbons; e.g. Q0C10H2 or
Q2H2. Apparently lower homologs are less effective sub-
strates because of a lesser affinity for the oxidation site. If
TMDMP indeed competes with the substrate for the binding
at the Qo site of the cytochrome bc1 complex, we would
expect it to be a more potent inhibitor when a less effective
substrate (lower homologs of ubiquinol) is used. To test this
idea we measured the inhibitory potency of TMDMP
against ubiquinol substrates with varying lengths of the
alkyl side chain (see Table 2). As predicted, when the alkyl
side chain length of substrate ubiquinol was decreased,
activity decreased and the percent activity inhibited by
TMDMP increased. These results further support binding
of TMDMP at the quinol oxidation site of the bc1 complex.
3.4. The effect of pH on the inhibition of the cytochrome bc1
complex by TMDMP and TMMDP
Titration of the activity of bc1 complex against pH shows
a bell-shaped curve with the pH ranging from 6.5 to 9.0.
The maximal activity is observed at pH 8.0, suggesting the
optimal condition for the substrate binding and the product
releasing at this pH, even though other factors may also
contribute to the maximal activity observed. If TMDMP
competes with substrate quinol for the Qo site of the bc1
complex, one would expect inhibition to be minimal at pH
8.0. To test this hypothesis, the inhibitor potencies of
TMDMP and TMMDP were determined at pH ranging
from 6.5 to 9.0 (see Fig. 5). In the presence of TMDMP
the enzyme complex exhibits bell-shaped pH curve, like the
free enzyme, but with lower activity. In the presence of 16.3
AM of TMDMP and a cytochrome bc1 complex concen-
tration of 2.0 nM, inhibition is 63.0% at pH 7.0, but only
33.0% at pH 8.0. An inverted bell-shaped curve is seen
when percent inhibition is plotted against pH. That is,
TMDMP inhibits least effectively when the complex is fully
active at pH 8.0. Similar pH dependence is observed with
TMMDP. These results further confirm that TMDMP or
TMMDP compete with substrate for its binding site in the
Fig. 3. TMDMP and TMMDP concentration-dependent inhibition of
ubiquinol–cytochrome c reductase. Twenty microliters of cytochrome bc1
complex, 0.05 mg/ml, in 50 mM phosphate buffer, pH 7.4, containing 1
mM EDTA and 0.01% dodecylmaltoside, was added to 975 Al of an assay
mixture with indicated amounts of TMDMP (4) or TMMDP (). The
reaction was started by the addition of 5 Al of 10 mM Q0C10H2. One
hundred percent activity represents 200 Amol cytochrome c reduced per
minute per milligram of protein.
Fig. 4. Lineweaver–Burk analysis of TMDMP and TMMDP inhibition on
cytochrome bc1 complex. Ten microliters of the bc1 complex, 0.05 mg/ml,
in 50 mM phosphate buffer, pH 7.4, containing 1 mM EDTA and 0.01%
dodecylmaltoside, was added to 975 Al of an assay mixture with no
inhibitor (o), 11.8 AM TMDMP (4) or 130 AM TMMDP (). The reaction
was started by the addition of various amounts of Q0C10H2.
Table 2
Effect of the length of the alkyl side chain of ubiquinol on the inhibition of







Q0C10 100 78.4 21.6
Q0C7 66 43.0 34.8
Q0C5 28 15.0 46.4
The concentrations of substrate and TMDMP used were 50 and 20 AM,
respectively.
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cytochrome bc1 complex since they compete less effectively
when the complex is at optimal pH condition, a situation
where substrate is most effectively bound.
As expected, inhibition of the cytochrome bc1 complex
by the currently available Qo site inhibitors, such as stigma-
tellin and myxothiazol, showed no such pH dependent in-
hibition curve because they are noncompetitive inhibitors.
Although inhibition of cytochrome bc1 by undecylhydrox-
ydioxobenzothiazole (UHDBT) is pH-dependent [25– 27],
the inhibition curve differs from that observed with TMDMP.
3.5. The lack of binding competition between TMDMP or
TMMDP and Qo site inhibitors
It was reported [26,28] that stigmatellin or UHDBT
binding induces cytochrome c1 oxidation in a partially
reduced cytochrome bc1 complex due to the elevation of
the Em of the ISP. An inhibitor, which competes with
stigmatellin but does not (or only slightly) elevate the Em
of ISP upon binding, should decrease or abolish the oxida-
tion of cytochrome c1 caused by stigmatellin. Addition of
TMDMP to a partially reduced cytochrome bc1 complex
Fig. 6. Binding competition between TMDMP and stigmatellin or UHDBT.
One milliliter of partially reduced cytochrome bc1 complex in 20 mM Tris–
Cl, pH 7.8, containing 100mM KCl, 0.05% dodecylmaltoside, was treated
sequentially with different inhibitors (fivefold molar excess). The redox
state of cytochrome c1 was monitored (553 minus 545 nm). Cytochrome c1
was about 70% reduced before addition of inhibitor. The final concentration
of cytochrome c1 is 5 AM.
Fig. 7. The relative binding location of TMDMP to those of other Qo site
inhibitors and redox centers in the cytochrome bc1 complex. The densities
of inhibitors at the Qo site are color-coded with TMDMP in red,
myxothiazol in green, stigmatellin in purple, UHDBT in blue and MOAS
in brown. The density for TMDMP comes from a Fourier synthesis electron
density map of TMDMP-treated crystals minus native bc1 crystals showing
a 6r peak for TMDMP. Residues (F325, W326, V329, L333 and T336) of
helix G and residues (M96, Y95, and I92) of helix D surround the cavity
opening for the TMDMP binding site.
Fig. 5. The effect of pH on the activity of the cytochrome bc1 complex in
the absence or presence of TMDMP or TMMDP. Ten microliters of the bc1
complex, 0.05 mg/ml, in 50 mM phosphate buffer, pH 7.4, containing 1
mM EDTA and 0.01% dodecylmaltoside, was added to 900 Al of an assay
mixture with the indicated pH’s containing no inhibitor (o), 16.3 AM
TMDMP (4) or 163.0 AM TMMDP (). The reaction was started by
addition of 48.5 AM Q0C10H2. The inhibition (4, ) was calculated as
percent of the control activity in the absence of the inhibitor, at the indicated
pH values.
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does not induce cytochrome c1 oxidation, suggesting that
binding of this inhibitor does not elevate the Em of ISP. The
lack of binding competition between TMDMP and stigma-
tellin or UHDBT is shown in Fig. 6. Note that the degree of
cytochrome c1 oxidation induced by treatment with stigma-
tellin or UHDBT is not altered by the presence of TMDMP,
regardless of the addition sequence. This result further
indicates nonidentical binding sites for these inhibitors.
Although the lack of effect of TMDMP or TMMDP on
UHDBT or stigmatellin binding can also be explained by the
large difference in binding affinity among these inhibitors,
preliminary results from X-ray crystallographic analysis of
TMDMP loaded crystals of cytochrome bc1 complex sup-
port the nonidentical binding site hypothesis.
3.6. Preliminary results on the TMDMP binding site
Fig. 7 shows the binding location of TMDMP in relation
to other Qo site inhibitors and the redox centers in the
complex. The binding site of TMDMP does not overlap
with the binding sites of stigmatellin, MOA-stilbene
(MOAS), UHDBT and myxothaizol. The binding site of
TMDMP coincides with one of the two peptides (P-47,
residues 142–155, and P-49, residues 326–336) of cyto-
chrome b identified by the photoactivated affinity labeling
technique using a radioactive azido-Q derivative [29]. P-47
is located in cd1 helix, which is close to the PEWY sequence
in the ef-loop of the 3-D structure of cytochrome b. Stigma-
tellin and several other Qo site inhibitors are located between
cd1 and ef-loop. P-49 is located in the transmembrane helix
G, which is located at the opening of the TMDMP binding
site. These results seem to be in line with the idea that more
than one quinol binding site [30,31] are involved in the
oxidation of quinol catalyzed by the cytochrome bc1 com-
plex; one at or near the stigmatellin binding site and another
at the TMDMP binding site. Detailed X-ray crystallographic
study of TMDMP (ubiquinol) binding site is currently in
progress and will be reported later.
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